Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results

Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray

February 8, 2017 9:12 AM EST

Piper Jaffray analyst William Quirk reaffirms Neutral rating and raises price target on Myriad Genetics (NASDAQ: MYGN) to $22 (from $21), noting 2017 fiscal second quarter numbers for the company were strong, but near-term risks remain.

Quirk comments, "MYGN is up ~15% in aftermarket trading after... More

Ladenburg Thalmann Upgrades Myriad Genetics (MYGN) to Neutral

February 8, 2017 6:42 AM EST

Ladenburg Thalmann upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $15.40 yesterday.

... More

Myriad Genetics (MYGN) Tops Q2 EPS by 2c

February 7, 2017 4:28 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.

GUIDANCE:

Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of... More